Hepatocellular carcinoma: From diagnosis to treatment

Miral Sadaria Grandhi, Amy Kim, Sean M. Ronnekleiv-Kelly, Ihab R Kamel, Mounes A. Ghasebeh, Timothy M. Pawlik

Research output: Contribution to journalArticle

Abstract

Primary liver cancer is the sixth most common cancer overall and the second most common cause of cancer mortality worldwide. Hepatocellular carcinoma accounts for up to 90% of all primary hepatic malignancies and represents a major international health problem. While surgical resection and transplantation are the cornerstone of therapy in early-stage hepatocellular carcinoma, locoregional therapy and sorafenib are beneficial in those with more advanced disease or those who are not surgical candidates. At times, the integration of both surgical and locoregional therapy may be necessary. Hence, hepatocellular carcinoma requires a multidisciplinary approach to determine the most appropriate treatment as well as the timing of various treatments for optimal outcomes.

Original languageEnglish (US)
Pages (from-to)74-85
Number of pages12
JournalSurgical Oncology
Volume25
Issue number2
DOIs
Publication statusPublished - Jun 1 2016

    Fingerprint

Keywords

  • Ablation
  • Functional MRI
  • Hepatocellular carcinoma
  • Liver transplantation
  • Sorafenib
  • Transarterial chemoembolization (TACE)

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Grandhi, M. S., Kim, A., Ronnekleiv-Kelly, S. M., Kamel, I. R., Ghasebeh, M. A., & Pawlik, T. M. (2016). Hepatocellular carcinoma: From diagnosis to treatment. Surgical Oncology, 25(2), 74-85. https://doi.org/10.1016/j.suronc.2016.03.002